- Home
- SWVL vs NVNO Comparison
SWVL vs NVNO Comparison
Compare SWVL & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- NVNO
- Stock Information
- Founded
- SWVL 2017
- NVNO 1987
- Country
- SWVL United Arab Emirates
- NVNO United States
- Employees
- SWVL N/A
- NVNO N/A
- Industry
- SWVL Business Services
- NVNO Medical/Dental Instruments
- Sector
- SWVL Consumer Discretionary
- NVNO Health Care
- Exchange
- SWVL Nasdaq
- NVNO Nasdaq
- Market Cap
- SWVL 37.6M
- NVNO 16.7M
- IPO Year
- SWVL N/A
- NVNO N/A
- Fundamental
- Price
- SWVL $3.58
- NVNO $0.90
- Analyst Decision
- SWVL
- NVNO
- Analyst Count
- SWVL 0
- NVNO 0
- Target Price
- SWVL N/A
- NVNO N/A
- AVG Volume (30 Days)
- SWVL 15.4K
- NVNO 2.4M
- Earning Date
- SWVL 09-08-2025
- NVNO 10-30-2025
- Dividend Yield
- SWVL N/A
- NVNO N/A
- EPS Growth
- SWVL N/A
- NVNO N/A
- EPS
- SWVL N/A
- NVNO N/A
- Revenue
- SWVL $19,329,423.00
- NVNO N/A
- Revenue This Year
- SWVL N/A
- NVNO N/A
- Revenue Next Year
- SWVL N/A
- NVNO N/A
- P/E Ratio
- SWVL N/A
- NVNO N/A
- Revenue Growth
- SWVL N/A
- NVNO N/A
- 52 Week Low
- SWVL $2.40
- NVNO $0.67
- 52 Week High
- SWVL $7.50
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- SWVL 45.34
- NVNO 25.14
- Support Level
- SWVL $3.31
- NVNO $0.67
- Resistance Level
- SWVL $4.01
- NVNO $0.93
- Average True Range (ATR)
- SWVL 0.29
- NVNO 0.07
- MACD
- SWVL 0.01
- NVNO 0.13
- Stochastic Oscillator
- SWVL 38.44
- NVNO 85.15
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.